These cells in turn lead to elevated integrin β1-FAK-Src activation in melanoma cells undergoing treatment, generating a drug-tolerant microenvironment that provides a ‘safe haven’ for melanoma cells51. This evidence concerns the gene PTK2 and melanoma.